Month: <span>September 2017</span>

Home / 2017 / September
Post

Targeted antibiotic use may help cure chronic myeloid leukaemia

The antibiotic tigecycline, when used in combination with current treatment, may hold the key to eradicating chronic myeloid leukaemia (CML) cells, according to new research. The University of Glasgow led study, published today in Nature Medicine, demonstrates the effectiveness of combining tigecycline with the drug imatinib – a tyrosine kinase inhibitor (TKI) and standard first-line treatment of patients...

Post

FDA OKs Glaxo’s inhaler, first one to combine three medicines

This photo provided by GlaxoSmithKline PLC shows the company’s Trelegy Ellipta inhaler. Late Monday, Sept. 18, 2017, the Food and Drug Administration approved the product, which is the first inhaler that combines three medicines to ease …more   The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients...

Post

Antioxidant supplement cost saving and effective for degenerative eye disease

A supplement that combines antioxidants with zinc and copper is a relatively inexpensive and effective means of halting the progression of a certain type of degenerative eye disease, concludes research published online in the British Journal of Ophthalmology. Given the costs and side effects of the current range of drugs used to treat the ‘wet’ form...

Post

Cancer drugs cost a QUARTER of the price that industry figures quote, a new study shows

Pharmaceutical companies tend to say a cancer drug costs $2.7billion But that highly-criticized figure was gathered from private data sets Now a study has found the average is actually around $650million Cancer drugs do not cost as much to produce as industry-sponsored research claims, according to a landmark analysis. Pharmaceutical companies often say it costs...

Post

Type 2 diabetics should take aspirin TWICE a day to prevent heart disease: Finding contradicts guidelines that recommend the anti-clotting drug once every 24 hours

When taken once a day, the risk of blood clots between doses is substantial Researchers advise taking the drug twice in a day to reduce clots between doses Participants who did not previously take aspirin were more at-risk of clotting  Blood clots can lead to cardiovascular disease, such as heart attacks and stroke The researchers...

Post

Cells programmed like computers to fight disease

This is a figure showing RNA sequence of command. Led by Professor Alfonso Jaramillo in the School of Life Sciences, new research has discovered that a common molecule — ribonucleic acid (RNA), which is produced abundantly by humans, plants and animals — can be genetically engineered to allow scientists to program the actions of a...

Post

Drug for type 2 diabetes provides significant benefits to type 1 diabetic patients

A majority of patients with Type 1 diabetes who were treated with dapagliflozin, a Type 2 diabetes medicine, had a significant decline in their blood sugar levels, according to a new study published in The Lancet Diabetes and Endocrinology. The results are being presented today by the University at Buffalo researcher who led the study at...

Post

New oral diabetes drug shows promise in phase 3 trial for patients with type 1 diabetes

A University of Colorado Anschutz Medical Campus study finds sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes. Principal results were published today in the New England Journal of Medicine of a global Phase 3 clinical trial in patients with type 1 diabetes treated with sotagliflozin. Sotagliflozin is an investigational...

Post

Skin patch dissolves ‘love handles’ in mice

Microneedle skin patch that delivers fat-shrinking drug locally could be used to treat obesity and diabetes Microneedle patch. Researchers have devised a medicated skin patch that can turn energy-storing white fat into energy-burning brown fat locally while raising the body’s overall metabolism. The patch could be used to burn off pockets of unwanted fat such...